Orbis Medicines
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
$93M Series A ·
Led by NEA · Source: startupintros.com
Total raised: $121M across 2 sourced rounds
All 2 rounds ↓Signals
Website registeredSep 9, 2021 (5 years old)
Funding rounds
- Series A · $93M
NNEA (lead),
CCormorant Asset Management,
EEli Lilly,
EExport and Investment Fund,
FForbion Capital Partners,
NNovo Holdings
Source: startupintros.com - Seed · $28M
FForbion Capital Partners (lead),
NNovo Holdings (lead)
Source: startupintros.com - Website created
Founders and team
SH
Sevan Habeshian FounderMG
Morten Graugaard Døssing CEODB
Daniela Brodbeck VP Discovery Biology and OperationsMD
Mikkel Dybkjær CFO/COOSN
Simon Nielsen Chief Development Officer
Investors
CCormorant Asset Management
EEli Lilly
EExport and Investment Fund
FForbion Capital Partnerslead investor
NNEAlead investor
NNovo Holdingslead investor
NNovo Nordisk
Companies like Orbis Medicines
EEntelo Bio$4M Seed · Apr 2026
EExcelsior Sciences$95M Series A · Dec 2025
OOMass Therapeutics$310M Series B+ · Oct 2026
DDigital Ether ComputingSeed · Jul 2026
YYSBiotikSeed · Mar 2026
MMeddenovoPre Seed · Jul 2024
Other companies backed by NEA
BBasalt Health$20M Series A · Oct 2026
PPathos$237M Series B+ · Oct 2026
TTamr$21M Series B+ · Oct 2026
SSpiko Paris, France$90M Series B+ · Oct 2026
AAutomating software development$200M Series B+ · Sep 2026
PPositron$875M Series B+ · Sep 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/orbis-medicines (get a free API key).